PCSA CEO buys 2,136 Processa Pharma shares

Processa Pharmaceuticals, Inc. director and Chief Executive Officer George K. Ng reported an open-market purchase of 2,136 shares of common stock at $2.535 per share.

Rhea-AI Filing Summary

Processa Pharmaceuticals, Inc. director and Chief Executive Officer George K. Ng reported an open-market purchase of 2,136 shares of common stock at $2.535 per share. After this transaction, he directly holds 2,136 shares. He also reports indirect ownership of 800 shares through the Ng Cha Family Trust and 3,488 shares through an account labeled George Ng IRRA FOB George Ng.

Insider Trade Summary

Net Buyer: 2,136 shares

Net Buy 3 txns

Insider Ng George K

Role Chief Executive Officer

Bought 2,136 shs ($5K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	2,136	$2.535	$5K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 2,136 shares (Direct); Common Stock — 3,488 shares (Indirect, George Ng IRRA FOB George Ng); Common Stock — 800 shares (Indirect, Ng Cha Family Trust)

Key Figures

Shares purchased: 2,136 shares Purchase price: $2.535 per share Direct holdings after transaction: 2,136 shares +3 more

6 metrics

Shares purchased 2,136 shares Open-market purchase of common stock

Purchase price $2.535 per share Price paid for 2,136 common shares

Direct holdings after transaction 2,136 shares Common stock held directly by George K. Ng

Indirect holdings via Ng Cha Family Trust 800 shares Common stock held indirectly

Indirect holdings via IRRA account 3,488 shares Common stock held indirectly in George Ng IRRA FOB George Ng

Net buy shares 2,136 shares Net buy direction in transaction summary

Key Terms

open-market purchase, indirect ownership, Form 4/A, transaction summary

4 terms

open-market purchase financial

"Purchase in open market or private transaction"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

indirect ownership financial

"direct_or_indirect: "I", nature_of_ownership: "Ng Cha Family Trust""

Form 4/A regulatory

"INSIDER FILING DATA (Form 4/A)"

Form 4/A is an amended filing that corrects or updates an earlier Form 4, the mandatory report that insiders (like company executives, directors, or large shareholders) must file when their ownership stakes change. Think of it as an edited receipt showing who bought or sold stock and when; investors use it to track insider confidence, detect potential conflicts, and spot trading patterns that might signal future company prospects.

transaction summary financial

""transactionSummary": { "buyCount": 1, "sellCount": 0"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did PCSA CEO George Ng report on this Form 4/A?

George K. Ng reported buying 2,136 shares of Processa Pharmaceuticals common stock in an open-market purchase at $2.535 per share. This filing also updates his direct and indirect holdings as of March 31, 2026, showing his current ownership positions.

How many Processa Pharmaceuticals (PCSA) shares does George Ng now hold directly?

Following the reported transaction, George K. Ng directly holds 2,136 shares of Processa Pharmaceuticals common stock. These shares were acquired in an open-market purchase at $2.535 per share and represent his directly owned position separate from any indirect holdings.

What indirect PCSA shareholdings are reported for George Ng in this filing?

The filing lists 800 shares of Processa Pharmaceuticals common stock held indirectly through the Ng Cha Family Trust. It also reports 3,488 shares held indirectly through an account described as George Ng IRRA FOB George Ng, indicating additional ownership outside his direct holdings.

What price did George Ng pay per share for his PCSA open-market purchase?

George K. Ng paid $2.535 per share for 2,136 shares of Processa Pharmaceuticals common stock in an open-market transaction. This price reflects the per-share consideration reported in the Form 4/A for the purchase on March 31, 2026, and defines the cost basis for these shares.

Does the PCSA Form 4/A show any insider stock sales by George Ng?

No insider stock sales are reported for George K. Ng in this Form 4/A. The filing shows one open-market purchase of 2,136 shares and two holding-only entries for existing indirect positions, indicating a net-buy direction for the period covered.

What is the overall buy versus sell activity for George Ng in this PCSA filing?

The transaction summary shows one buy transaction totaling 2,136 shares and no sales. Two additional entries simply record indirect holdings. Overall, the Form 4/A reflects a net-buy position for George K. Ng during the reported period for Processa Pharmaceuticals.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/30/2026 - 04:32 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ng George K

(Last) (First) (Middle)

C/O PROCESSA PHARMACEUTICALS, INC.

601 21ST STREET SUITE 300

(Street)

VERO BEACH FLORIDA 32960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
04/01/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/31/2026		P		2,136	A	$2.535	2,136	D
Common Stock								3,488	I	George Ng IRRA FOB George Ng
Common Stock								800	I	Ng Cha Family Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ George Ng, by John J. Wolfel, as Attorney-in-Fact	04/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)